Interleukin Genetics,
Inc. (Amex: ILI), announced the launch of an enhanced test report
format and information package for the company's Heart Health Genetic Test.
The test is currently marketed under the brand name Gensona(R) Heart Health
Genetic Test by Quixtar/Amway. The new report will include quantified risk
information on heart attack and coronary artery disease generated from
clinical studies and conducted by the company. The company believes that
this enhanced report format will provide individuals and their physicians
more complete information about a person's inflammation-based genetic risk
factor for a heart attack. The new package also provides information on the
science behind the genetic test and information to help people understand
preventive measures and actions that can be taken to lower the risk of
heart disease.
In addition, the company will conduct scientific lectures on the
Gensona(R) test for interested Quixtar/Amway individual business owners at
their scheduled conferences. The first of these lectures will be on
Saturday morning and afternoon, July 26, 2008 at the
Nardone/Melillo/Callendar conference at the Radisson Valley Forge Hotel &
Convention Center in Valley Forge, PA. Thousands of attendees are expected
at the conference.
Lewis H. Bender, Chief Executive Officer at Interleukin Genetics,
commented, "Heart disease is by far the leading killer of Americans.
Individuals with different interleukin gene variations have vastly
different clinical trajectories for heart disease progression. The ability
to know your individual genetic predisposition for this disease is a new
and powerful tool to allow a customer and their physicians to design the
best preventive care for that person."
About Coronary Artery Disease
Coronary artery disease (CAD) is an inflammatory disease in which
plaque builds up inside the coronary arteries. These arteries supply your
heart muscle with oxygen-rich blood. Plaque is made up of fat, cholesterol,
and other substances found in the blood. When plaque builds up in the
arteries, the condition is called atherosclerosis. Variation in interleukin
genes has shown to be associated with different degrees of CAD risk. Over
time, CAD can weaken the heart muscle and lead to heart attack and
arrhythmias. CAD is the most common type of heart disease and is the
leading cause of death in the United States for both men and women.
Lifestyle changes, medicines, and/or medical procedures can effectively
prevent or treat CAD in most people. Certain cholesterols have also been
associated with increased CAD risk. According to the American Heart
Association, over 105 million American adults have total blood cholesterol
values of 200 mg/dL and higher, and 36.6 million American adults have
levels of 240 or above. Doctors consider total cholesterol levels of 240
mg/dL or greater high in adults and levels from 200 to 239 mg/dL
borderline-high.
About Interleukin Genetics
Interleukin Genetics, Inc. (Amex: ILI), is a genetics-focused
personalized health company that develops preventive consumer products and
genetic tests for sale to the emerging personalized health market. Focused
on the future of health and medicine, Interleukin uses its leading genetics
research and scientific capabilities to develop and test innovative
preventive and therapeutic products. Interleukin currently offers an array
of Nutraceuticals and OTCeuticals(R), including Ginkoba(R), Ginsana(R) and
Venastat(R) which are sold at the nation's largest food, drug and mass
retailers, and has commercialized genetic tests for periodontal disease
risk assessment, cardiovascular risk assessment, and general nutrition
assessment. Interleukin is headquartered in Waltham, MA. For more
information about Interleukin, its products and ongoing programs, please
visit ilgenetics.
Certain statements contained herein are "forward-looking" statements
including statements regarding our ability to develop diagnostic,
personalized nutritional and therapeutic products to prevent or treat
diseases of inflammation and other genetic variations, our ability to
screen nutritional compounds for their effects on inflammatory responses
and other genetic variations, given specific genetic patterns and our
ability to make progress in advancing our core technologies. Because such
statements include risks and uncertainties, actual results may differ
materially from those expressed or implied by such forward-looking
statements. Factors that could cause actual results to differ materially
from those expressed or implied by such forward-looking statements include,
but are not limited to, the risk of market acceptance of our products, the
risk of technology and product obsolescence, delays in product development,
the performance of our commercial partners, the availability of adequate
capital, the actions of our competitors and other competitive risks, and
those risks and uncertainties described in our annual reports on Form 10-K,
our quarterly reports on Form 10-Q and other documents we file with, or
furnish to, the Securities and Exchange Commission. We disclaim any
obligation or intention to update these forward-looking statements.
Interleukin Genetics, Inc.
ilgenetics